Oncolytics® Biotech Inc. issues 33rd U.S. patent

Oncolytics® Biotech Inc. issues 33rd U.S. patent

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) has been granted its 33rd U.S. Patent, No. 7,608,257, entitled “Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus.” The patent claims cover methods of using reovirus in combination with currently approved chemotherapeutic agents to treat patients that are refractory to those chemotherapeutic agents alone.

Read the release.

Filed under: Business of Biotech, ,